【摘要】 目的探讨卵巢肿瘤患者血浆溶血磷脂酸(lysophosphatidic acid,LPA)水平及其受体Edg-4在卵巢肿瘤组织中的表达情况。方法2002-01-2004-01扬州大学临床医学院测定57例卵巢恶性肿瘤患者、66例卵巢良性肿瘤患者及37例健康对照者血浆LPA水平和血清CA125水平,比较两者在诊断卵巢恶性肿瘤中的敏感性和特异性。并用RT-PCR方法检测其中18例卵巢恶性肿瘤患者及24例卵巢良性肿瘤患者肿瘤组织Edg-4mRNA的表达情况。结果卵巢恶性肿瘤患者、卵巢良性肿瘤患者及健康对照者血浆LPA水平分别为(5.63±2.35)μmol/L、(2.80±1.13)μmol/L、(2.51±1.08)μmol/L,前者血浆LPA水平与后两者相比,差异有统计学意义(P<0.01);后两者之间血浆LPA水平差异无统计学意义(P>0.05)。LPA和CA125在诊断卵巢恶性肿瘤的敏感性和特异性方面差异无统计学意义(P>0.05)。18例卵巢恶性肿瘤患者肿瘤组织中有16例Edg-4mRNA表达阳性,24例卵巢良性肿瘤患者肿瘤组织中有11例Edg-4mRNA表达阳性,两者在Edg-4mRNA表达方面差异有统计学意义(P<0.01)。结论卵巢恶性肿瘤患者血浆LPA水平明显高于良性肿瘤患者和健康对照者;大多数卵巢恶性肿瘤患者表达Edg-4受体,部分卵巢良性肿瘤患者表达Edg-4受体,血浆LPA及其受体Edg-4可能成为治疗卵巢恶性肿瘤的新靶点。更多还原

【Abstract】 Objective To investigate the levels of lysophosphatidic acid (LPA) present in plasma and the expression of LPA receptor Edg-4 in tumor from patients with ovarian tumor. Methods We measured LPA levels in plasma and CA- 125 levels in serum from 57 patients with ovarian carcinoma,66 patients with ovarian benign disease and 37 healthy control women in the Clinical Medical College of Yangzhou University from January 2002 to January 2004 and compared the sensitivity and specificity of plasma LPA levels and serum CA- 125 levels in diagnosing ovarian carcinoma. The mRNA expression of Edg-4 in ovary of 18 patients with ovarian carcinoma and 24 patients with ovarian benign disease were detected by the method of RT-PCR. Results Patients in ovarian carcinoma group had significantly higher plasma LPA levels (5.63±2.35)μmol/L compared with the ovarian benign disease group(2.80±1.13)μmol/L(P<0.01), and healthy control group (2.51±1.08) μmol/L(P<0.01). There were no significant differences in plasma LPA levels between patients with ovarian benign disease and healthy control women (P>0.05). LPA and CA- 125 had the similar sensitivity and specificity in diagnosing the ovarian carcinoma. The mRNA expression of Edg-4 showed statistically significant differences (P<0.01). Conclusion Plasma LPA levels of patients with ovarian carcinoma are significantly higher than those of patients with ovarian benign disease and healthy control. The expression of Edg-4 is detected in most of ovarian carcinoma and in part of ovarian disease. Plasma LPA and its Edg-4 receptor might be therapeutic targets for treating ovarian malignant tumor.更多还原